Market
U.S. subsidiary and expanded U.K. trial footprint come as development costs mount Repeated convertible bond conversions add dilution and potential selling pressure

Mezzion is expanding its operations by separating a U.S. entity and broadening the clinical footprint for new indications of udenafil, but critics say the moves come against a backdrop of mounting financial pressure from the prolonged Fontan therapy trial and stock dilution tied to convertible bond (CB) conversions.
On Sept. 23, Mezzion said it had established Mezzion Biotech, a wholly owned U.S. subsidiary dedicated to developing a treatment for autosomal dominant polycystic kidney disease (ADPKD) and managing global business operations. The plan is to separate it from Mezzion Pharmaceuticals, the existing entity dedicated to Fontan therapy, assign a separate corporate value to the follow-on pipeline, and explore independent external investment, an equity sale or even a local listing.
Earlier, in early September, the company expanded the countries participating in FUEL-2, a global confirmatory phase 3 trial in patients with Fontan syndrome, from South Korea and the U.S. to three pediatric cardiac hospitals in London and Birmingham, England. The move is intended to accelerate patient enrollment.
The problem is that the fallout from repeated mezzanine financing continues to weigh on the market. On Oct. 7, the conversion of domestic private-placement CBs will result in the additional listing of 127,278 common shares.
In May, Mezzion issued 36.5 billion won in unsecured private-placement CBs to secure funding for clinical operations. The company initially sought to raise 80 billion won by forming a new technology business investment partnership, but struggled to attract investors. Even after switching to a conventional mezzanine financing structure, the amount raised fell short of half the original target.
The continued influx of new shares not only dilutes existing shareholders’ ownership value but also creates an overhang risk — potential selling pressure — that can limit the stock’s upside.
The funding model through the newly established subsidiary also faces questions about whether its prospects are overly optimistic. Mezzion points to Novartis’ acquisition of Regulus and Roche’s acquisition of Telavant to emphasize the potential sale value of a pipeline-focused company.
However, both global examples were backed by clear clinical results or early equity participation from a major multinational pharmaceutical company. By contrast, Mezzion’s polycystic kidney disease pipeline is at a very early stage: after animal-model studies, it is only now preparing to enter phase 2b trials in South Korea and the U.S.
The intention is to ease the parent company’s research and development cost burden by creating a separate entity, but it remains uncertain whether the subsidiary can secure independent funding at an attractive valuation from local venture capital firms or global biopharmaceutical companies.
The FUEL-2 trial of Fontan therapy, the key determinant of udenafil’s prospects, will also require considerable time and funding to complete. Mezzion voluntarily withdrew its U.S. Food and Drug Administration (FDA) application in March 2022 and then narrowed its target population for another attempt.
The challenges of managing the trial timeline were substantial: the company had to expand recruitment to hospitals in England because of the characteristics of this difficult-to-recruit patient population. Although Mezzion says it increased the likelihood of success by excluding super-Fontan patients with near-normal exercise capacity and adjusting statistical criteria, concerns remain that existing funds may not be enough to see the program through commercialization, given the costs of reporting results and resubmitting the application.
Ultimately, establishing a subsidiary and expanding the trial in England are attempts to diversify a business structure heavily concentrated on a single molecule, udenafil. But unless the core business achieves its fundamental goal of final approval for Fontan therapy, the moves risk being only stopgap measures.
Whether the company completes patient enrollment early and whether the polycystic kidney disease subsidiary entering phase 2b secures external funding will be key measures of the company’s chronic cash-flow uncertainty.

BIOBOOK TEAM
biobookmedia@biobook.co.kr
Charles River Acquires Two Frontage Bioanalytical Laboratories for $470 Million

Sanofi-Backed Windward Raises $225 Million in IPO to Develop Respiratory Drugs From China

PharmaResearch Reports Third-Quarter Operating Profit of KRW 186.4 Billion, Up 14.7% Year Over Year

Hanmi Pharmaceutical’s Operating Profit Reaches ₩222.6 Billion in First Three Quarters, Up 27.5% Year Over Year

Kolon TissueGene Posts 73.3 Billion Won in Net Income Through Q3, Returns to Profit

BlueMtec Posts 5.5 Billion Won in Net Income Through Q3, Returning to Profit From a Year-Earlier Loss